Bacillus anthracis and Bacillus cereus are the most important species of the genus Bacillus involved in human infections. They are spore-forming Gram-positive rods, characterized by the ability to produce endospores. Some species are obligate aerobes and others are facultative anaerobes. The heat-and chemical-resistant spores make the genus an important cause of spoilage and contamination of medical supplies. Bacillus cereus is often the unrecognized cause of food-borne disease, and the incubation time usually varies from 4 to 17 h.
This patient received an unrelated bone marrow graft, which was transported from the USA to Brazil. In a study, which screened platelet units, Yomtovian et al 7 observed that magnitude and rate of contamination were significantly higher if these units were transfused after 4 days of storage. Rowley et al 2 described the bactericidal properties of bone marrow, capable of protection against overwhelming bacterial growth. However, prolonged storage at room temperature may affect the ability of the bone marrow to suppress bacterial growth. 2 In this case, the time from collection to symptoms of infection was approximately 33 h. Since bacterial reproduction follows an exponential growth model, the bacterial load at the time of infusion may have led to the clinical picture observed.
Unrelated marrow transplants, frequently implicating long distances between donor and recipient, are more common nowadays. Thus, the harvested marrow may be a potential risk of emerging infections. 8 Storage of bone marrow on ice, maintaining temperature around 15°C, 9 and in vitro decontamination using pretested antibiotics, should be alternatives to decrease or even eliminate bacterial contamination. 10 Although this is the first report of septic shock due to unrelated bone marrow graft contamination, the clinician must be alert, especially if a long time from collection to infusion is encountered. Moreover, in the event of early signs of bacteremia or shock, antimicrobial therapy must be instituted aggressively to prevent serious consequences. 
TBI, etoposide and cyclophosphamide as a promising conditioning regimen for BMT in childhood ALL in second remission
With its strong anti-leukaemic activity and propensity for diffusion to the central nervous system (CNS), etoposide (VP-16) has been proven to be effective when combined with TBI, with or without CY, as conditioning for BMT in acute leukaemias. [1] [2] [3] The combined use of a topoisomerase inhibitor (VP-16) together with an alkylating agent (CY) in a TBI-based conditioning regimen may represent an effective approach towards virtually eliminating the leukaemic clone. 2 Most available data concern experiences in adult patients, while little information is available in children. [1] [2] [3] [4] [5] [6] [7] [8] [9] However, a recent study published in this journal, proved the feasibility and efficacy of TBI-VP 16-CY in paediatric patients with different types of acute leukaemias at various stages. 10 Our single-centre experience confirms the safety and efficacy of this conditioning regimen in children with ALL in 2nd CR, demonstrated by the transplantedrelated mortality (TRM) and disease-free survival (DFS) estimations.
Between April 1995 and December 1999, 28 children with ALL in 2nd CR, underwent either allogeneic BMT from an HLA-identical sibling (12 patients) or autologous stem cell transplantation (four BM and 12 PBSC). Informed consent was obtained for all children, signed by their parents. For patients who received autologous PBSC grafts from 1997 onwards, peripheral blood (CD34 + ) progenitor cells were selected adopting a new two-step negative purification method.
11 All patients were given intensive chemotherapy first-line protocols at diagnosis, according to BFM schedules.
12,13 Site of relapse among patients undergoing allogeneic BMT was BM in six cases, BM plus CNS in two, BM plus testis in one and isolated CNS in three cases. In the autologous transplantation group, site of relapse among patients undergoing PBSC was BM in six, BM plus CNS in one, BM plus other sites (eyes or testis) in two cases, CNS isolated in one case and testis isolated in two cases, and among those undergoing ABMT was BM in two cases and BM plus CNS in two cases. The median time from diagnosis to relapse was 26 months (range 11-102 months) and 36 months (range 15-78 months) for allogeneic and autologous transplantation, respectively. All patients underwent second-line chemotherapy after relapse, based on an induction schedule with idarubicin and Ara-C 14 and a 2 to 3 month consolidation course according to BFM chemotherapy protocols.
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Median age at transplantation was 8 years and the male: female ratio was 17:11. The following schedule was adopted: TBI: 200 cGy twice a day, for 3 consecutive days, on days −7, −6, −5 before transplant (total dose 12 Gy); VP-16: 60 mg/kg once daily i.v. as a 4 to 8 h infusion, on day −4; CY: 50 mg/kg once daily i.v., for 2 consecutive days, on days −3 and −2 (total dose 100 mg/kg). All patients who underwent allogeneic BMT received CsA at a dose of 3 mg/kg/day by continuous i.v. infusion, as GVHD prophylaxis. Median time to myeloid engraftment (ANC Ͼ500/l) was 13 days for both allogeneic and autologous transplants. Median time to platelet engraftment (platelets Ͼ25 000/l) was 16 and 18 days for allogeneic and autologous transplantation, respectively. At the end of April 2000, 10/12 allografted patients (83.3%) were alive in CR (with a median observation time of 26 months, range 5-49 months), which results in a DFS of 80.2 at 2 years (standard error 12.8); one patient relapsed and died 1 year after transplantation, and another died 14 months after BMT due to multiple-organ failure caused by extensive chronic GVHD and thrombotic thrombocytopenic purpura. Eleven out of 16 autografted patients (68.7%) are alive in CR (with a median observation time of 24 months, range 6-36 months), which results in a DFS of 62.5 at 2 years (standard error 13.9); four patients relapsed and died (2/12 who received PBSC and 2/4 who underwent ABMT); another patient relapsed after autologous PBSC transplant and underwent a second unrelated BMT, but died from veno-occlusive disease. Overall, 9/12 patients who received autologous PBSC grafts are alive in CR with the same observation time as the whole autografted group. TRM occurred in 1/12 patients (8.3%) undergoing allogeneic BMT and in no children undergoing autologous transplantation. Transplant-related toxicity was evaluated according
